GlassScriptPhysician profile
Johnathon T Markus
NPI 1548521461
$17,210.55
in general payments reported to CMS, 2019-2025
45 companies · $3,965 in 2025
The $3,965 reported for 2025 was more than what 98% of Hospitalist providers received nationally (typical 2025 total: $85.87).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,589 · 2020: $304 · 2021: $1,364 · 2022: $2,960 · 2023: $3,301 · 2024: $3,726 · 2025: $3,965.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,992.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $4,612.42 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $2,109.90 | 2019-2025 | Xifaxan, Plenvu, Trulance |
| Takeda Pharmaceuticals U.S.A., INC. | $1,820.76 | 2019-2025 | Entyvio, Eohilia, Gattex |
| Janssen Biotech, INC. | $1,542.89 | 2019-2025 | Stelara, Tremfya, Simponi Aria |
| Pfizer INC. | $852.67 | 2019-2025 | |
| Ardelyx, INC. | $781.48 | 2022-2025 | Ibsrela |
| Genzyme Corporation | $776.45 | 2022-2025 | |
| Gilead Sciences, INC. | $602.73 | 2019-2025 | |
| Qol Medical, LLC | $537.11 | 2019-2025 | Sucraid, Sucraid |
| Regeneron Healthcare Solutions, INC. | $482.34 | 2022-2025 | Dupixent |
| Celgene Corporation | $464.50 | 2021-2024 | Zeposia |
| Intercept Pharmaceuticals, INC. | $384.65 | 2020-2025 | Ocaliva |
| Braintree Laboratories, INC. | $305.16 | 2019-2024 | Sutab, Suflave |
| Lilly USA, LLC | $236.59 | 2024-2025 | Omvoh |
| Phathom Pharmaceuticals, INC. | $138.86 | 2023-2025 | Voquezna |
Show all 45 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ferring Pharmaceuticals INC. | $129.94 | 2021-2024 | Rebyota |
| Aimmune Therapeutics, INC. | $115.92 | 2024-2025 | Zenpep, Vowst |
| Merck Sharp & Dohme LLC | $109.47 | 2021-2024 | Dificid |
| Evoke Pharma, INC. | $103.33 | 2022-2025 | |
| Ipsen Biopharmaceuticals, INC | $101.49 | 2024-2025 | Iqirvo |
| Nestle Healthcare Nutrition INC. | $100.35 | 2021-2023 | |
| Madrigal Pharmaceuticals | $94.48 | 2024-2025 | Rezdiffra, Resmetirom |
| Daiichi Sankyo INC. | $90.96 | 2021-2025 | Injectafer |
| Vivus LLC | $80.47 | 2021-2025 | Qsymia |
| Amgen INC. | $57.70 | 2022 | |
| Novo Nordisk INC | $55.67 | 2020-2025 | Wegovy |
| Fresenius Kabi USA, LLC | $52.85 | 2023 | |
| Organogenesis INC. | $45.40 | 2025 | Puraply Wound Matrix |
| Celltrion USA INC. | $43.85 | 2025 | Vegzelma |
| Ucb, INC. | $38.18 | 2019 | |
| Organon LLC | $35.67 | 2024 | |
| Redhill Biopharma INC. | $35.44 | 2022-2023 | Aemcolo, Movantik, Talicia |
| Shionogi INC | $34.66 | 2019 | |
| Cook Medical LLC | $32.73 | 2021 | |
| Mauna Kea Technologies, INC. | $26.08 | 2024 | |
| W. L. Gore & Associates, INC. | $21.67 | 2023 | Gore Cardioform Septal Occluder |
| Boston Scientific Corporation | $20.05 | 2025 | Resolution 360 Clip |
| Mylan Institutional INC. | $20.00 | 2023 | Hulio |
| Concordia Pharmaceuticals INC. | $19.21 | 2019 | |
| Ironwood Pharmaceuticals, INC | $18.75 | 2021 | |
| Capsovision, INC. | $18.49 | 2024 | Capsocam Plus |
| Csl Behring | $17.61 | 2019 | |
| Lucid Diagnostics INC. | $15.93 | 2024 | |
| Exact Sciences Corporation | $14.66 | 2025 | Cologuard Collection Kit |
| Micro-Tech Endoscopy USA, INC. | $11.03 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Johnathon Markus listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.